STOCK TITAN

[SCHEDULE 13G] Assembly Biosciences, Inc SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G
Rhea-AI Filing Summary

Farallon-affiliated investment vehicles and related persons reported aggregate ownership of 1,140,510 shares of Assembly Biosciences (ASMB), representing the position disclosed across the filing. The group also holds 510,205 Class A Warrants (currently exercisable subject to a 4.99% beneficial ownership limitation) and 510,205 Class B Warrants (exercisable beginning on a future date), for a total of 1,020,410 warrants that could convert into additional shares subject to the limitation.

The Schedule 13G is filed under the passive-investor provision, and the filers state the warrants are assumed not exercisable within 60 days for beneficial-ownership calculations. The filing lists the Farallon Funds, their general partners, and numerous individual Farallon managers as reporting persons and discloses shared voting and dispositive power over the reported shares.

Veicoli d'investimento affiliati a Farallon e persone correlate hanno dichiarato una partecipazione complessiva di 1.140.510 azioni di Assembly Biosciences (ASMB), corrispondente alla posizione indicata nella comunicazione. Il gruppo detiene inoltre 510.205 Warrant Classe A (attualmente esercitabili, soggetti a un limite di proprietà effettiva del 4,99%) e 510.205 Warrant Classe B (esercitabili a partire da una data futura), per un totale di 1.020.410 warrant che potrebbero convertirsi in azioni aggiuntive, soggette al medesimo limite.

La Schedule 13G è stata presentata come investimento passivo; i firmatari dichiarano che, ai fini del calcolo della proprietà effettiva, i warrant sono considerati non esercitabili entro 60 giorni. La comunicazione elenca i Farallon Funds, i loro general partner e numerosi dirigenti Farallon come persone che riportano la posizione e indica il possesso congiunto dei poteri di voto e di disposizione sulle azioni dichiarate.

Vehículos de inversión afiliados a Farallon y personas relacionadas informaron una participación agregada de 1.140.510 acciones de Assembly Biosciences (ASMB), que representa la posición divulgada en la presentación. El grupo también posee 510.205 Warrants Clase A (actualmente ejercitables, sujetos a un límite de propiedad beneficiaria del 4,99%) y 510.205 Warrants Clase B (ejercitables a partir de una fecha futura), sumando 1.020.410 warrants que podrían convertirse en acciones adicionales, sujeto al límite.

La Schedule 13G se presentó bajo la disposición de inversor pasivo, y los declarante afirman que los warrants se consideran no ejercitables dentro de 60 días para los cálculos de propiedad beneficiaria. La presentación enumera los Farallon Funds, sus socios generales y numerosos directivos de Farallon como personas que informan, y revela el poder compartido de voto y disposición sobre las acciones reportadas.

Farallon 계열 투자 기구 및 관련 인사들은 Assembly Biosciences(ASMB)의 총 1,140,510주를 보유하고 있다고 신고했으며, 이는 제출서에 기재된 보유 내역을 의미합니다. 해당 그룹은 또한 510,205개의 클래스 A 워런트(현재 행사 가능하나 4.99% 실질소유 제한 적용)와 510,205개의 클래스 B 워런트(향후 행사 가능)를 보유하고 있어, 총 1,020,410개의 워런트가 추가 주식으로 전환될 수 있으나 제한의 적용을 받습니다.

Schedule 13G는 수동 투자자 조항에 따라 제출되었으며, 제출자들은 실질소유 계산을 위해 워런트는 60일 이내 행사 불가능한 것으로 가정된다고 명시했습니다. 제출서에는 Farallon 펀드들, 그들의 일반 파트너 및 다수의 Farallon 관리자들이 보고자(persons reporting)로 기재되어 있으며, 신고된 주식에 대한 공동 의결권 및 처분권을 보유하고 있음이 공개되어 있습니다.

Des véhicules d'investissement affiliés à Farallon et des personnes liées ont déclaré une détention agrégée de 1 140 510 actions d'Assembly Biosciences (ASMB), correspondant à la position divulguée dans le dépôt. Le groupe détient également 510 205 bons de souscription de Classe A (exerçables actuellement, sous réserve d'une limitation de participation bénéficiaire de 4,99 %) et 510 205 bons de souscription de Classe B (exerçables à partir d'une date ultérieure), soit un total de 1 020 410 bons susceptibles d'être convertis en actions supplémentaires, sous réserve de la limitation.

Le formulaire Schedule 13G a été déposé au titre de la disposition « investisseur passif » ; les déclarants indiquent que, pour le calcul de la participation bénéficiaire, les bons sont présumés non exerçables dans les 60 jours. Le dépôt énumère les Farallon Funds, leurs partenaires généraux et de nombreux managers Farallon comme personnes déclarante et révèle un pouvoir conjoint de vote et de disposition sur les actions déclarées.

Farallon-nahe Investmentvehikel und zugehörige Personen meldeten einen Gesamtbestand von 1.140.510 Aktien von Assembly Biosciences (ASMB), entsprechend der in der Meldung offenbarten Position. Die Gruppe hält außerdem 510.205 Class-A-Warrants (derzeit ausübbar, unterliegen einer 4,99% Beschränkung der wirtschaftlichen Eigentümerschaft) und 510.205 Class-B-Warrants (ab einem späteren Zeitpunkt ausübbar), somit insgesamt 1.020.410 Warrants, die in zusätzliche Aktien umgewandelt werden könnten, vorbehaltlich der Beschränkung.

Die Schedule 13G wurde unter der Regelung für passive Investoren eingereicht; die Einreichenden geben an, dass die Warrants für Zwecke der Berechnung der wirtschaftlichen Eigentümerschaft als innerhalb von 60 Tagen nicht ausübbar angesehen werden. Die Einreichung nennt die Farallon Funds, deren General Partner und zahlreiche Farallon-Manager als meldende Personen und legt gemeinschaftliche Stimm- und Verfügungsrechte an den gemeldeten Aktien offen.

Positive
  • Aggregate disclosed stake of 1,140,510 shares provides clear, material ownership transparency
  • Substantial warrant holdings (1,020,410 total) are disclosed, showing potential future share conversion
  • Filing under Schedule 13G (passive) and an explicit certification that holdings are not intended to influence control
Negative
  • None.

Insights

TL;DR: Farallon disclosed a meaningful passive stake in ASMB with substantial warrant exposure, limited by a 4.99% ownership cap.

The filing shows the Farallon group holds 1,140,510 shares and 1,020,410 warrants convertible into shares subject to a contractual Beneficial Ownership Limitation of 4.99%. Because the report is filed under the passive Schedule 13G route, the group affirms the position is not held to influence control. For investors, the combination of direct shares plus warrants signals potential incremental demand for shares if warrants become exercisable and the ownership cap permits further conversion, but the current beneficial-ownership calculation excludes the warrants due to timing and the 60-day exercisability assumption.

TL;DR: Robust disclosure of ownership structure and reliance on passive-investor classification reduces immediate governance concerns.

The Schedule 13G identifies multiple fund entities, their general partners, and 17 individual Farallon managers as reporting persons, with the filers explicitly stating a passive intent. The filing clarifies shared voting/dispositive power across funds and disclaims affirmative group formation while attaching a joint acquisition statement. From a governance perspective, this level of transparency and the passive filing status suggest no immediate coordination to change control, though the presence of sizable shared positions warrants monitoring for any future Section 13D amendments.

Veicoli d'investimento affiliati a Farallon e persone correlate hanno dichiarato una partecipazione complessiva di 1.140.510 azioni di Assembly Biosciences (ASMB), corrispondente alla posizione indicata nella comunicazione. Il gruppo detiene inoltre 510.205 Warrant Classe A (attualmente esercitabili, soggetti a un limite di proprietà effettiva del 4,99%) e 510.205 Warrant Classe B (esercitabili a partire da una data futura), per un totale di 1.020.410 warrant che potrebbero convertirsi in azioni aggiuntive, soggette al medesimo limite.

La Schedule 13G è stata presentata come investimento passivo; i firmatari dichiarano che, ai fini del calcolo della proprietà effettiva, i warrant sono considerati non esercitabili entro 60 giorni. La comunicazione elenca i Farallon Funds, i loro general partner e numerosi dirigenti Farallon come persone che riportano la posizione e indica il possesso congiunto dei poteri di voto e di disposizione sulle azioni dichiarate.

Vehículos de inversión afiliados a Farallon y personas relacionadas informaron una participación agregada de 1.140.510 acciones de Assembly Biosciences (ASMB), que representa la posición divulgada en la presentación. El grupo también posee 510.205 Warrants Clase A (actualmente ejercitables, sujetos a un límite de propiedad beneficiaria del 4,99%) y 510.205 Warrants Clase B (ejercitables a partir de una fecha futura), sumando 1.020.410 warrants que podrían convertirse en acciones adicionales, sujeto al límite.

La Schedule 13G se presentó bajo la disposición de inversor pasivo, y los declarante afirman que los warrants se consideran no ejercitables dentro de 60 días para los cálculos de propiedad beneficiaria. La presentación enumera los Farallon Funds, sus socios generales y numerosos directivos de Farallon como personas que informan, y revela el poder compartido de voto y disposición sobre las acciones reportadas.

Farallon 계열 투자 기구 및 관련 인사들은 Assembly Biosciences(ASMB)의 총 1,140,510주를 보유하고 있다고 신고했으며, 이는 제출서에 기재된 보유 내역을 의미합니다. 해당 그룹은 또한 510,205개의 클래스 A 워런트(현재 행사 가능하나 4.99% 실질소유 제한 적용)와 510,205개의 클래스 B 워런트(향후 행사 가능)를 보유하고 있어, 총 1,020,410개의 워런트가 추가 주식으로 전환될 수 있으나 제한의 적용을 받습니다.

Schedule 13G는 수동 투자자 조항에 따라 제출되었으며, 제출자들은 실질소유 계산을 위해 워런트는 60일 이내 행사 불가능한 것으로 가정된다고 명시했습니다. 제출서에는 Farallon 펀드들, 그들의 일반 파트너 및 다수의 Farallon 관리자들이 보고자(persons reporting)로 기재되어 있으며, 신고된 주식에 대한 공동 의결권 및 처분권을 보유하고 있음이 공개되어 있습니다.

Des véhicules d'investissement affiliés à Farallon et des personnes liées ont déclaré une détention agrégée de 1 140 510 actions d'Assembly Biosciences (ASMB), correspondant à la position divulguée dans le dépôt. Le groupe détient également 510 205 bons de souscription de Classe A (exerçables actuellement, sous réserve d'une limitation de participation bénéficiaire de 4,99 %) et 510 205 bons de souscription de Classe B (exerçables à partir d'une date ultérieure), soit un total de 1 020 410 bons susceptibles d'être convertis en actions supplémentaires, sous réserve de la limitation.

Le formulaire Schedule 13G a été déposé au titre de la disposition « investisseur passif » ; les déclarants indiquent que, pour le calcul de la participation bénéficiaire, les bons sont présumés non exerçables dans les 60 jours. Le dépôt énumère les Farallon Funds, leurs partenaires généraux et de nombreux managers Farallon comme personnes déclarante et révèle un pouvoir conjoint de vote et de disposition sur les actions déclarées.

Farallon-nahe Investmentvehikel und zugehörige Personen meldeten einen Gesamtbestand von 1.140.510 Aktien von Assembly Biosciences (ASMB), entsprechend der in der Meldung offenbarten Position. Die Gruppe hält außerdem 510.205 Class-A-Warrants (derzeit ausübbar, unterliegen einer 4,99% Beschränkung der wirtschaftlichen Eigentümerschaft) und 510.205 Class-B-Warrants (ab einem späteren Zeitpunkt ausübbar), somit insgesamt 1.020.410 Warrants, die in zusätzliche Aktien umgewandelt werden könnten, vorbehaltlich der Beschränkung.

Die Schedule 13G wurde unter der Regelung für passive Investoren eingereicht; die Einreichenden geben an, dass die Warrants für Zwecke der Berechnung der wirtschaftlichen Eigentümerschaft als innerhalb von 60 Tagen nicht ausübbar angesehen werden. Die Einreichung nennt die Farallon Funds, deren General Partner und zahlreiche Farallon-Manager als meldende Personen und legt gemeinschaftliche Stimm- und Verfügungsrechte an den gemeldeten Aktien offen.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Farallon Capital Partners, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Managing Member of its General Partner
Date:08/15/2025
Farallon Capital Institutional Partners, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Managing Member of its General Partner
Date:08/15/2025
Farallon Capital Institutional Partners II, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Managing Member of its General Partner
Date:08/15/2025
Farallon Capital Institutional Partners III, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Managing Member of its General Partner
Date:08/15/2025
Four Crossings Institutional Partners V, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Manager of its General Partner
Date:08/15/2025
Farallon Capital Offshore Investors II, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Managing Member of its General Partner
Date:08/15/2025
Farallon Capital (AM) Investors, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Managing Member of its General Partner
Date:08/15/2025
Farallon Capital F5 Master I, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Manager of its General Partner
Date:08/15/2025
Farallon Partners, L.L.C.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Managing Member
Date:08/15/2025
Farallon Institutional (GP) V, L.L.C.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Manager
Date:08/15/2025
Farallon F5 (GP), L.L.C.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Manager
Date:08/15/2025
Dapice Joshua J.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/15/2025
Dreyfuss, Philip D.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/15/2025
Dunn Hannah E.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn
Date:08/15/2025
Fried, Richard B
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/15/2025
Gehani, Varun N.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/15/2025
Giauque, Nicolas
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/15/2025
Kim, David T.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/15/2025
Linn, Michael G.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/15/2025
Luo Patrick (Cheng)
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/15/2025
Patel, Rajiv A.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/15/2025
Roberts, Jr., Thomas G.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/15/2025
Saito Edric C.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/15/2025
Seybold, William
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/15/2025
Short Daniel S.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/15/2025
Spokes, Andrew J. M.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/15/2025
Warren, John R.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/15/2025
Wehrly, Mark C.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/15/2025
Exhibit Information

Exhibit 1. Joint Acquisition Statement Pursuant to Section 240.13d-1(k)

FAQ

How many Assembly Biosciences (ASMB) shares does Farallon report owning?

The filers report aggregate ownership of 1,140,510 shares of ASMB.

Does Farallon hold warrants that could convert into ASMB shares?

Yes. The filing discloses 510,205 Class A Warrants and 510,205 Class B Warrants, totaling 1,020,410 warrants that may convert into shares subject to a beneficial ownership cap.

What ownership percentage does the filing show for the reporting persons?

Individual cover pages show percentages such as 7.3% for certain reporting persons and 7% for the Farallon Partners entity, with other funds reporting smaller percentages; the aggregate positions are disclosed on each cover page.

Are the warrants counted in the beneficial ownership total?

No. The Reporting Persons state they assumed the warrants are not exercisable within 60 days and therefore did not include them in the reported beneficial ownership due to the 4.99% Beneficial Ownership Limitation.

Under which rule was this Schedule 13G filed?

The filing states it was submitted pursuant to Section 240.13d-1(c), the passive-investor provision.
Assembly Bioscie

NASDAQ:ASMB

ASMB Rankings

ASMB Latest News

ASMB Latest SEC Filings

ASMB Stock Data

189.89M
12.56M
39.25%
12.97%
0.4%
Biotechnology
Pharmaceutical Preparations
Link
United States
SOUTH SAN FRANCISCO